Tag: celiac disease
AMYRA Publishes Landmark Review Supporting New Gluten Digestion Approach for Celiac Disease
— Findings highlight underexplored role of intestinal brush border in protein digestion, and its vulnerability to inflammatory damage in celiac disease
— Review discusses potential benefits of supplementing brush border exopeptidase activity in celiac disease patients
AMYRA Biotech AG, a leader in pioneering approaches to digestive health, today announced it published a peer-reviewed literature review in Alimentary Pharmacology & Therapeutics [https://onlinelibrary.wiley.com/doi/10.1111/apt.70014]. The review summarizes current knowledge on gluten-digesting enzyme therapies for celiac disease and underlines the benefits of exploring exopeptidase supplementation as a novel therapeutic paradigm. Read more…
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
— Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical study
— AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical enzymes on the lining of the intestinal brush border
AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal diseases announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP in Frontiers in Immunology – Nutritional Immunology(https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1425982/full). AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine. AMYNOPEP is designed to break down hard-to-digest gluten peptides into harmless and absorbable single amino acids and dipeptides, thereby supporting individuals with gluten-related health disorders in avoiding exposure to inflammatory peptides. Read more…
Allero Therapeutics Receives EIC Horizon Grant to Advance Treatment of Celiac Disease
– Specific OroMucosal ImmunoTherapy (SOMIT) for celiac disease patients supported with EUR 2.5mn funding
Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced that the Company has received a EUR 2.5 million EIC Horizon Grant provided by the European Commission to advance novel treatments for celiac disease patients. The program is based on Allero´s proprietary SOMIT (Specific OroMucosal ImmunoTherapy) platform technology for the treatment of antigen-driven immune disorders.